DMHCA，25MG，SML4114-25MG，Sigma

Biochem/physiol Actions

Orally active liver X receptor LXRα/β agonist that selectively induces ABCA1 gene transcriptional activation over that of SREBP-1c in vitro and in vivo.


DMHCA, a synthetic oxysterol, is an orally active liver X receptor (LXR) agonist (LXRα/β EC50 = 2 µM by reporter assays using respective CV-1 transfectants; LXRα/β Ki = 130/100 nM) that, unlike GW3965 & T0901317, preferentially induces ATP-binding cassette transporter ABCA1 gene transcriptional activation over that of SREBP-1c both in vitro and in mice in vivo. Long-term DMHCA administration significantly reduces lesion formation in male and female apoE-deficient mice (80 mg/kg/day via chow diet) without increasing hepatic triglyceride (TG) levels.